Home › Aimmune Therapeutics Announces Positive Phase 2 Study Results Of AR101 For The Treatment Of Peanut Allergy
 

Keywords :   


Aimmune Therapeutics Announces Positive Phase 2 Study Results Of AR101 For The Treatment Of Peanut Allergy

2015-06-17 06:39:17| foodingredientsonline Home Page

Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced recently that a Phase 2 study (ARC001) evaluating the company’s lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively

Tags: of results study positive

Category:Food and Related Products

Latest from this category

All news
»
17.05China takes sweeping action to ease property crisis
17.05LOréal Patents Hybrid Mineral and Organic Sunscreen
17.05Telefónica pay TV accesses down 45,000 in 1Q 2024
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
17.05Reddit shares jump after OpenAI ChatGPT deal
17.05Is China's bubble tea bubble about to burst?
17.05Is China's bubble tea bubble about to burst?
More »